|
|
| 36-Month Efficacy of Nadofaragene in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer |
|
Yair Lotan, MD
|
| Yair Lotan joins Zachary Klaassen to discuss the 36-month follow-up data of nadofaragene firadenovec for BCG-unresponsive bladder cancer. The phase 3 trial evaluates the long-term efficacy and safety of nadofaragene, an intravesical adenovirus vector administered every three months, in patients with carcinoma in situ and papillary disease. |
|
|
|
|
|
|
|
|
|
|
|
| BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence |
|
Ali Nasrallah, MD
|
| Ali Nasrallah discusses the BRAVO study (Bladder Cancer Recurrence Analysis in Veterans and Outcomes). The study examines the real-world impact of blue light cystoscopy versus white light cystoscopy in non-muscle invasive bladder cancer patients within the VA healthcare system. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights from the 2024 South Central Section of the AUA Annual Meeting |
|
|
|
|
| Bladder Cancer Recurrence Analysis in Veterans and Outcomes (BRAVO): White Light Versus Blue Light Cystoscopy Outcomes Among NMIBC Patients in an Equal Access Setting |
| Ali Nasrallah, MD |
| The BRAVO study presented at SCS AUA 2024 examined blue light vs. white light cystoscopy outcomes in veterans with NMIBC. Results showed that blue light cystoscopy significantly reduced the 3-year recurrence risk compared to white light (75% vs. 67%) and led to greater use of intravesical therapies, although progression rates remained similar. This real-world data supports blue light cystoscopy as a beneficial tool for recurrence reduction in NMIBC management. |
|
|
|
|
|
|
|
|
|
|
| Efficacy of Intravesical Nadofaragene Firadenovec-VNCG for Patients with BCG-Unresponsive NMIBC: 36-Month Follow-Up from a Phase 3 Trial
|
| Yair Lotan, MD
|
| At the 36-month follow-up in a phase 3 trial, nadofaragene firadenovec demonstrated efficacy and safety as a bladder-preserving treatment for BCG-unresponsive NMIBC. In patients with CIS, 53.4% achieved a complete response at 3 months, with 25.5% of responders remaining recurrence-free by month 36. The Ta/T1 cohort showed similar results, with 31% of early responders remaining recurrence-free at 36 months, and over half of patients overall achieving cystectomy-free survival.
|
|
|
|
|
|
| Real-World Treatments Following BCG Induction in Patients with NMIBC: A Contemporary US Claims Analysis |
| Amanda Myers, MD |
| Amanda Myers presented findings from a US claims analysis showing that ~63% of NMIBC patients received adequate BCG induction, yet only 25% received maintenance BCG. Nearly 40% of patients had no further treatment post-BCG, and bladder-preserving therapies were more common than radical cystectomy. The study highlights significant treatment variation and underscores the need for further research as new bladder-preserving therapies emerge.
|
|
|
|
|
|
| Adjuvant Immunotherapy in High-Risk Muscle Invasive Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
|
| Carlos Riveros, MD
|
| Carlos Riveros presents a meta-analysis of adjuvant immunotherapy in high-risk muscle-invasive urothelial carcinoma (MIUC) at the 2024 South Central AUA annual meeting. Reviewing data from three RCTs with 2,220 patients, the study highlighted the disease-free survival (DFS) advantage of adjuvant immune checkpoint inhibitors (ICIs) versus observation, particularly in the CheckMate-274 and AMBASSADOR trials, showing a pooled hazard ratio of 0.76 (95% CI 0.65-0.90) for DFS.
|
|
|
|
|
|
| Urothelial Carcinoma of the Prostate and Intravesical Therapy: A Cautionary Tale |
| Amanda Myers, MD |
| Amanda Myers presented findings at the 2024 South Central AUA meeting on high-grade urothelial carcinoma of the prostate in NMIBC patients treated with bladder-sparing intravesical therapy. Among 42 patients, 71% experienced recurrence within a median of 8.5 months, and 40% required cystectomy by a median of 10.3 months. Dr. Myers emphasized the high recurrence and progression rates and the need for vigilant follow-up for patients receiving bladder-sparing treatments in this high-risk setting. |
|
|
|
|
|
